The effects of minimal intermittent heparinization and of conventional heparinization on endogen fibrinogen concentration as well as on fibrin depositis were studied on 17 on patients hemodialysis. It was shown that the minimal intermittent heparinization did non reduce dialysis efficiency and that a total heparin dosage of 6,000 units is the lowest safe limit.
AlbertF.W.: Anticoagulatientherapie bei Langzeit-Haemodialysierten (auch Diabetiker). In: Niere, Blutgerinnung und Haemostase Herausgeber: Marx R., H.A., ThiesSchattauer, Stuttgart-New-York325, 1978.
2.
BradleyJ., HickmanJ.A.: Behaviour of commercially prepared l-125-fibrinogen in metabolic studies.J. Clin. Path.28, 487, 1975.
3.
BullM.H., HuseW.M., BullB.S.: Evaluation of tests used to monitor heparin therapy during extracorporeal circulation.Anesthesiology43, 346, 1975
4.
ButtermannG.: Untersuchungen zur medikamentösen Prophylaxe post-operativer Thrombosen und Embolien.Habilitation Schrift, Techn. Univ. München1976.
5.
BrögliH.: Der Mechanismus des sogenannten “Heparin Rebound” nach extrakorporalem Kreislauf.Thrombos. Diathes, Haemorrh.13, 40, 1965.
6.
ChampionH., LongW., SmithH., SaccoW., NyikosP., CowleyR.A., GillW.: Indication for early hemodialysis in multiple trauma.Lancet1, 1125, 1974.
7.
CollenD., TytgatG.N., ClaeysH., Piessens.: Metabolism and distribution of fibrinogen. I. Fibrinogen turnover under phyisiological conditions in humans.Brit. J. Haemat.22, 681, 1972.
CongdonJ.E., KardinalC.G., WallinJ.D.: Monitoring heparin therapy in hemodialysis.J.A.M.A.13, 1529, 1973.
10.
DavisL.J.: Monitoring during low-dose heparin prophylaxis. New Engl.J. Med.293, 776, 1975.
11.
FratantoniJ.S., WesslerS. (eds.): Prophylactic therapy of deep vein thrombosis and pulmonary embolism. DHEW Publication No. (NIH) 76 - 866. US Government Printing Office1975.
12.
GodalH.C.: Heparin assay methods for control of in vivo heparin effects.Thrombos. Diathes. Haemorrh.33, 77, 1974.
13.
GonzalesF.M., LeeJ.H., CockeT.B.: Regional vs “tight” heparinization in hemodialysis.Proc. Dial. Transpl. Forum239, 1974.
14.
GordonL.A., RichardsV., PerkinsH.A.: Studies in regional heparinization.N. Engl. J. Med.255, 1025, 1956.
HillJ.D., DontignyL., de LevalM., MielckeC.A.Jr..: A simple method of heparin management during prolonged extracorporeal circulation.Ann. Thor. Surg.17, 129, 1974.
17.
HillerE.: überwachung der Heparintherapie bei thromboembolischen Erkrankungen.Dtsch. med. Wschr.98, 1367, 1973.
18.
HirschJ., GallusA.S.: Letter to the editor.N. Engl. J. Med.228, 1410, 1973.
19.
JaquesL.B.: Standardization of heparin of clinical use.LancetI, 2871975.
20.
JägerR., PfefferG., KoppK.F.: Vollblut-APTT und minimal intermittierende Heparinisierung zur Gerinnungskontrolle im extrakorporalen Kreislau:Nieren und Hochdruck5, 234, 1980.
21.
KakkarV.V.: The diagnosis of deep vein thrombosis using the l-125-fibrinogen test.Arch. Surg.104, 152, 1972.
22.
KakkarV.V.: Low dose heparin in the prevention of venous thromboembolism.Thrombos. Diathes. Haemorrh.33, 87, 1975.
23.
KesslerM., HieplerE., JaenickeJ.: Untersuchungen zur isolierten Heparinisierung bei der extracorporalen Dialyse.Klin. Wschr.40, 467, 1962.
24.
KissJ.: Chemistry of heparin: A short review on recent chemical trends.Thrombos. Diathes. Haemorrh. (Stuttgart)33, 20, 1974.
25.
Korsgaard ChristensenL.: The turnover of plasma fibrinogen.Act. Med. Scand. Vol. CLXII, fasc. V 1958.
26.
KösteringH., WaltherCh., QuelhorstE., WiggerW., SchelerF.: Antikoagulatienbehandlung zur Vermeidung von Shunt-Thrombosierungen bei Haemodialyse-patienten.Med. Klin.65, 2012, 1970.
27.
KuhlmannH.: Behandlung der diabetischen Glomerulosklerose (Kimmelstiel-Wilson-Syndrom).Dtsch. Med. Wschr.101, 1769–1772, 1976.
Mac AulayM.A., FrischC.R., KlionskyB.L.: Relationship of the partial thromboplastin time to the Lee-White coagulation time.Am. J. clin. Path.50, 9, 1968.
33.
NoseY.: Die künstliche Niere.de Gruyter, Berlin-New York1974.
34.
RayP., HarperT.: Comparison of activated recalcification and partial thromboplastin test as controls of heparin therapy.J. Lab. Clin. Med.77, 901, 1971.
35.
RodmanN.F.Jr., BarrowE.M., GrahamJ.B.: Diagnosis and control of the hemophiloid states with the partial thromboplastin (PTT) test.Am. J. Clin. Path.29, 525, 1958.
36.
RosenbergR.D.: Actions and interactions of antithrombin and heparin.N. Engl. J. Med.292, 146, 1975.
37.
SaggauW., EnckeA.: Veränderung der Blutgerinnung bei Patienten mit chronischen Nierenekrankungen und Haemodialyse.Med. Welt.23, 91, 1972.
38.
SchrieverH.G., EpsteinS.E., MintzM.D.: Statistical correlation and heparin-sensitivity of activated partial thromboplastin time, whole blood coagulation time and an automated coagulation time.Am. J. Clin. Path.60, 323, 1973.
39.
ShapiroW.B., FaubertP.F., PorushJ.G., ChouShyan-yih: Low-Dose Heparin in routine hemodialysis monitored by activated partial thromboplastin time.Artificial Organs, Vol.3, 73–77, 1979.
40.
SeilerK., BlumbergA.: Kontrolle der rigionalen Heparinisierung der Haemodialyse mit einer vereinfachten Thrombinzeitbestimmung.Dtsch. Med. Wschr.97, 283, 1972.
41.
SpectorJ., CornU.: Control of heparin therapy with activated partial thromboplastin time.J.A.M.A.3, 75, 1967.
42.
StreicherE.: Organisation von Dialyseabteilungen. In: FranzH.E.: Praxis der DialysebehandlungThieme, Stuttgart1973.
43.
StruverG.P., BittnerD.L.: The partial thromboplastin time (cephalin time) in anticoagulation therapy.Am. J. Clin. Path.38, 473, 1962.
44.
TeienA.N., LieM.: Heparin assay in plasma: a comparison of live clotting methods.Thromb. Res.7, 777, 1975.
45.
VogelG.E., KoppK.F.: Minimal dose heparinization for hemodialysis with high bleeding risk.Abstract Europ. Dial. Transpl. Ass. (Copenhagen)77, 1975.
46.
VogelG.E., HansenW., GoldmannF.L., KoppK.F.: Die Heparinisierung des chronischen Dialysepatienten.Med. Klin.72, 1617, 1977.
47.
VogelG.E., KoppK.F.: The conflict between anticoagulantion and hemostasis during hemodialysis.
48.
VogelG.E.: Die Heparinisierung bei der Haemodialyse.Habilitation-Schrift der Techn. Univ. München1979.
49.
VogelG.E., ButtermannG., KommCh., KuhlencordtM., BlümelG., OberdorferA.: Praktische Durchfürung einer Heparinisierung im extracorporalen Kreislauf.Blut.42, 112, 1981.
50.
VonendE., BöttcherD., KnüdlerU., HeinzeV.: Veränderungen der plasmatischen Gerinnung und der Thrombozytenfunktion bei niereninsuffizienten Patienten.Med. Welt.25, 91, 1974.
51.
WesslerS., YinE.T.: On the antithrombin action of Heparin.Thrombos. Diathes. Haemorrh. (Stuttgart)32, 71, 1974.
52.
WesslerS.: Heparin as an antithrombotic agent- Low-dose prophylaxis.J.A.M.A., 236, 1976.
53.
WillimannP., AligA., BinswangerU.: Minimal intermittent heparinization during hemodialysis.Nephron23, 191, 1979.
54.
WilsonJ.W.: Heparin sodium - a review. (The continuing battle for standardization). J. Extra-Corp.Tech.4, 207, 1974.
55.
YinE.T., WesslerS.: Investigation of the apparat thrombogenicity of thrombin.Thrombos. Diathes. Haemorrh.20, 465, 1968.
56.
YinE.T., WesslerS.: Heparin-accelerated inhibition of activated factor X by its natural plasma inhibitor.Biochem. Biophys. Acta201, 387, 1970.
57.
YinE.T., WesslerS., ButlerJ.V.: Plasma heparin: A unique, practical, submicrogramsensitive assay. J. of Lab.Clin. Med.81, 298, 1973.
58.
ZuckerM.B.: Effect of heparin on platelet function.Thrombos. Diathes. Haemorrh.33, 63, 1974.
59.
ZuckerS., CatheyH.: Control of heparin therapy, sensitivity of activated partial thromboplastin time for monitoring the antithrombotic effects of heparin.J. Lab. Clin. Med.73, 320, 1969.
